Savant Capital LLC Has $35.90 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Savant Capital LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 0.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 248,256 shares of the company’s stock after purchasing an additional 729 shares during the period. Savant Capital LLC’s holdings in Johnson & Johnson were worth $35,903,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Angeles Wealth Management LLC lifted its stake in Johnson & Johnson by 2.1% in the 4th quarter. Angeles Wealth Management LLC now owns 16,166 shares of the company’s stock valued at $2,338,000 after purchasing an additional 329 shares during the last quarter. Tevis Investment Management increased its holdings in shares of Johnson & Johnson by 2.1% during the fourth quarter. Tevis Investment Management now owns 17,692 shares of the company’s stock worth $2,559,000 after buying an additional 358 shares in the last quarter. Legacy Financial Strategies LLC lifted its stake in shares of Johnson & Johnson by 6.4% in the 4th quarter. Legacy Financial Strategies LLC now owns 4,073 shares of the company’s stock valued at $587,000 after acquiring an additional 245 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $518,000. Finally, Kestra Private Wealth Services LLC grew its position in Johnson & Johnson by 5.9% during the 4th quarter. Kestra Private Wealth Services LLC now owns 110,408 shares of the company’s stock worth $15,967,000 after acquiring an additional 6,187 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company dropped their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $155.23 on Thursday. The stock has a market capitalization of $373.73 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock’s 50 day moving average price is $147.48 and its two-hundred day moving average price is $156.01.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.